Effect of intravitreal injection of bevacizumab on chronic central chorioretinopathy

Abstract

The aim of this study was the effect of in vitro injection of bevacizumab in the treatment of chronic central retinopathy is. Materials and Methods: In this retrospective study, patients with a diagnosis of serous central retinopathy who underwent in vitro injection of bevacizumab from 2016 to 2020 were included in the study. Patients were injected who did not respond to routine treatment and could not perform PDT laser. Improved vision of patients before and after injection was measured by Snelln chart and log MAR unit was used for statistical comparison. Subretinal fluid height was measured before and one month after in vitro injection of bevacizumab by Optical Coherence Tomography (OCT). Results: In this study, 17 patients were studied, according to the results of which 12 patients were male (70.6%) and 5 patients were female. In this study, the mean age of the subjects was 47.00 ± 6.80 years. In this study, bevacizumab injection significantly improved patients' vision and also significantly reduced subretinal fluid thickness and central medulla thickness.